HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression.

Abstract
Increased evidence indicates that chemokines are involved in tumor growth. ITAC, a key member of chemokines, possesses the ability to recruit T cells and enhance immune responses. Therefore, ITAC might contribute to antitumor immunity. In this study, we evaluated the relationship between the expression of ITAC and human breast cancer advancement. We further investigated whether forced expression of ITAC in tumor sites could mediate enhanced antitumor immunity in a murine breast cancer model. Results showed that ITAC expression level was down-regulated in 31 breast cancer specimens compared to normal mammary tissues, and associated negatively with the stages of breast cancer. Contrarily, forced expression of ITAC in murine 4T1 tumor cells resulted in tumor regression after initial growth upon injection into naïve Balb/c mice. More lymphocytes were recruited to the site of tumor inoculated by 4T1-ITAC and more than 80% of these T cells expressed the ITAC receptor, CXCR3. ITAC-recruited TILs exhibited 4T1-specific proliferation and cytotoxicity, and an increased IFN-gamma but decreased IL-4 production. Importantly, forced expression of ITAC in 4T1 tumor nodules inhibited tumor growth. These findings demonstrated that the decreased expression of ITAC is associated with the advancement of breast cancer in patients. Forced expression of ITAC in tumor site not only induces increased T cell-recruitment and elicits a specific antitumor immunity, but also mediates regression of established 4T1 tumors, indicating the potential application of ITAC-expressing tumor cells in cancer immunotherapy and vaccine designing.
AuthorsYiwei Chu, Xiuli Yang, Wei Xu, Ying Wang, Qiang Guo, Sidong Xiong
JournalCancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 56 Issue 10 Pg. 1539-49 (Oct 2007) ISSN: 0340-7004 [Print] Germany
PMID17659370 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CXCL11 protein, human
  • CXCR3 protein, human
  • Chemokine CXCL11
  • Chemokines, CXC
  • Cxcl11 protein, mouse
  • Cxcr3 protein, mouse
  • Receptors, CXCR3
  • Receptors, Chemokine
Topics
  • Animals
  • Breast Neoplasms (immunology, pathology, therapy)
  • Cell Line, Tumor
  • Cell Transplantation
  • Chemokine CXCL11
  • Chemokines, CXC (metabolism)
  • Chemotaxis, Leukocyte
  • Disease Models, Animal
  • Down-Regulation
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Receptors, CXCR3
  • Receptors, Chemokine (metabolism)
  • T-Lymphocytes (immunology)
  • Vaccination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: